Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how effective Olaparib is when given as a treatment
for primary or recurrent, unresectable or metastatic melanoma. This research study involves
targeted therapy.
-The name of the study drug involved in this study is: Olaparib (also known as Lynparza)